Loading...
XBRUBIOS
Market cap2mUSD
Dec 20, Last price  
0.01EUR
1D
3.28%
1Q
-22.22%
Jan 2017
-99.92%
IPO
-99.97%
Name

Bone Therapeutics SA

Chart & Performance

D1W1MN
XBRU:BIOS chart
P/E
—
P/S
3.76
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
78.27%
Rev. gr., 5y
-11.50%
Revenues
543k
+104.14%
0000041,0001,000,00001,000,0001,000,000266,000543,000
Net income
-29m
L+1,310.00%
-3,689,000-4,079,000-5,734,000-14,144,000-12,989,000-12,752,000-14,218,000-10,461,000-11,940,000-12,925,000-2,041,000-28,778,000
CFO
-3m
L+81.68%
-4,050,000-3,274,000-3,524,000-11,765,000-11,369,000-11,018,000-12,901,000-10,400,000-16,082,000-12,784,000-1,910,000-3,470,000
Earnings
Mar 04, 2025

Profile

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
URL
http://www.bonetherapeutics.com/
IPO date
Feb 06, 2015
Employees
20
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
543
104.14%
266
-73.40%
1,000
0.00%
Cost of revenue
7,582
1,709
13,465
Unusual Expense (Income)
NOPBT
(7,039)
(1,443)
(12,465)
NOPBT Margin
Operating Taxes
(7)
(1,016)
89
Tax Rate
NOPAT
(7,032)
(427)
(12,554)
Net income
(28,778)
1,310.00%
(2,041)
-84.21%
(12,925)
8.25%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,500
(22)
3,286
BB yield
-17.89%
0.19%
-23.15%
Debt
Debt current
11,821
5,058
1,046
Long-term debt
17,465
17,008
20,362
Deferred revenue
Other long-term liabilities
80
71
112
Net debt
28,759
20,097
11,886
Cash flow
Cash from operating activities
(3,470)
(1,910)
(12,784)
CAPEX
(5)
(207)
Cash from investing activities
6
1,952
(204)
Cash from financing activities
1,735
1,045
7,850
FCF
(4,808)
(314)
(13,191)
Balance
Cash
117
1,846
10,710
Long term investments
410
123
(1,188)
Excess cash
500
1,956
9,472
Stockholders' equity
(28,405)
(1,351)
(76,564)
Invested Capital
33,941
25,380
90,709
ROIC
ROCE
EV
Common stock shares outstanding
137,038
120,132
21,311
Price
0.06
-36.25%
0.10
-85.59%
0.67
-74.38%
Market cap
8,387
-27.28%
11,533
-18.74%
14,193
-53.44%
EV
37,353
31,270
26,162
EBITDA
(6,796)
(1,383)
(12,279)
EV/EBITDA
Interest
5,954
278
845
Interest/NOPBT